{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:43:13Z","timestamp":1790026993818,"version":"4.0.1"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301416"],"award-info":[{"award-number":["82301416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.semcancer.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T19:05:01Z","timestamp":1738955101000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Reshaping the immune microenvironment and reversing immunosenescence by natural products: Prospects for immunotherapy in gastric cancer"],"prefix":"10.1016","volume":"110","author":[{"given":"Zhipeng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-4459","authenticated-orcid":false,"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.02.002_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fcell.2020.00812","article-title":"MicroRNA: another pharmacological avenue for colorectal cancer?","volume":"8","author":"Wu","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2023.06.005","article-title":"Exosomes: another intercellular lipometabolic communication mediators in digestive system neoplasms?","volume":"73","author":"Li","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.semcancer.2025.02.002_bib3","doi-asserted-by":"crossref","first-page":"8281718","DOI":"10.1155\/2021\/8281718","article-title":"Oleanolic acid induces autophagy and apoptosis via the AMPK-mTOR signaling pathway in colon cancer","volume":"2021","author":"Hu","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106777","article-title":"Research progress on the interaction between oxidative stress and platelets: another avenue for cancer?","volume":"191","author":"Zhang","year":"2023","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12935-021-02416-7","article-title":"Glucose starvation suppresses gastric cancer through targeting miR-216a-5p\/Farnesyl-Diphosphate Farnesyltransferase 1 axis","volume":"21","author":"Zhao","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.semcancer.2025.02.002_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.781824","article-title":"Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer","volume":"9","author":"Mei","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.845261","article-title":"Adjuvant chemotherapy in pT2N0M0 gastric cancer: findings from a retrospective study","volume":"13","author":"Mei","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.semcancer.2025.02.002_bib8","article-title":"circDNMT1 Promotes malignant progression of gastric cancer through targeting miR-576-3p\/Hypoxia Inducible Factor-1 Alpha Axis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.02.002_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s13402-023-00835-4","article-title":"LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing","volume":"46","author":"Deng","year":"2023","journal-title":"Cell Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib10","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2025.02.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/jcmm.16217","article-title":"Piezo type mechanosensitive ion channel component 1 facilitates gastric cancer omentum metastasis","volume":"25","author":"Wang","year":"2021","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.semcancer.2025.02.002_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semcancer.2023.04.009","article-title":"Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology","volume":"93","author":"Wang","year":"2023","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.02.002_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2022.03.039","article-title":"Effect of helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up","volume":"163","author":"Yan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semcancer.2025.02.002_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2017.12.019","article-title":"ECCO essential requirements for quality cancer care: oesophageal and gastric cancer","volume":"122","author":"Allum","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.02.002_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.semcancer.2025.02.002_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","article-title":"Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin\u00ae) in recurrent ovarian, tubal, or peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"146","author":"Cohn","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10111","key":"10.1016\/j.semcancer.2025.02.002_bib21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.semcancer.2025.02.002_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.semcancer.2025.02.002_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.semcancer.2025.02.002_bib24","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.semcancer.2025.02.002_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semcancer.2024.07.005","article-title":"Brain macrophage senescence in glioma","volume":"104-105","author":"Li","year":"2024","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2024.07.004","article-title":"Gut microbiota and immunosenescence in cancer","volume":"104-105","author":"Xu","year":"2024","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semcancer.2024.08.006","article-title":"Combined targeting of senescent cells and senescent macrophages: a new idea for integrated treatment of lung cancer","volume":"106-107","author":"Gu","year":"2024","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semcancer.2024.10.003","article-title":"Ferroptosis and immunosenescence in colorectal cancer","volume":"106-107","author":"Wang","year":"2024","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2024.07.001","article-title":"T cell exhaustion and senescence for ovarian cancer immunotherapy","volume":"104-105","author":"Zhao","year":"2024","journal-title":"Semin Cancer Biol."},{"issue":"15","key":"10.1016\/j.semcancer.2025.02.002_bib30","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/0008-5472.CAN-07-5769","article-title":"Impaired dendritic cell function in aging leads to defective antitumor immunity","volume":"68","author":"Grolleau-Julius","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2025.02.002_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101422","article-title":"Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?","volume":"71","author":"Santoro","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.semcancer.2025.02.002_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2025.01.002","article-title":"Fungi, immunosenescence and cancer","author":"Xu","year":"2025","journal-title":"Semin Cancer Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc3497","article-title":"How ageing processes influence cancer","volume":"13","author":"de Magalh\u00e3es","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.semcancer.2025.02.002_bib34","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1016\/j.cell.2024.06.025","article-title":"\"Boosting\" tumor immunity in elderly mice by hyperactivating dendritic cells","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib35","article-title":"Identifying an immunosenescence-associated gene signature in gastric cancer by integrating bulk and single-cell sequencing data","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2025.02.002_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154612","article-title":"Natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents","volume":"109","author":"Liu","year":"2023","journal-title":"Phytomedicine"},{"issue":"26","key":"10.1016\/j.semcancer.2025.02.002_bib37","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1080\/10408398.2021.1913091","article-title":"Natural products targeting into cancer hallmarks: an update on caffeine, theobromine, and (+)-catechin","volume":"62","author":"Cadon\u00e1","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"2","key":"10.1016\/j.semcancer.2025.02.002_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41419-022-04608-z","article-title":"Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/nu14051023","article-title":"The steroidal alkaloid tomatidine and tomatidine-rich tomato leaf extract suppress the human gastric cancer-derived 85As2 cells in vitro and in vivo via modulation of interferon-stimulated genes","volume":"14","author":"Fujimaki","year":"2022","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.semcancer.2025.02.002_bib40","first-page":"944","article-title":"Transcriptional profiling and network pharmacology analysis identify the potential biomarkers from Chinese herbal formula Huosu Yangwei Formula treated gastric cancer in vivo","volume":"19","author":"Fang","year":"2021","journal-title":"Chin. J. Nat. Med"},{"key":"10.1016\/j.semcancer.2025.02.002_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.156","article-title":"Gut microbiota reshapes cancer immunotherapy efficacy: mechanisms and therapeutic strategies","volume":"3","author":"Xie","year":"2024","journal-title":"Imeta"},{"issue":"6","key":"10.1016\/j.semcancer.2025.02.002_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"issue":"10142","key":"10.1016\/j.semcancer.2025.02.002_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib47","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib48","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-019-0508-1","article-title":"Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial","volume":"7","author":"Chung","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.02.002_bib50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.02.002_bib51","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"19","key":"10.1016\/j.semcancer.2025.02.002_bib53","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1078-0432.CCR-19-2443","article-title":"Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","article-title":"Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.semcancer.2025.02.002_bib56","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.02.002_bib57","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","article-title":"Efficacy of pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with programmed death ligand 1 combined positive score \u2265\u200910","volume":"27","author":"Wainberg","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch. Pathol. Lab Med"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib59","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2025.02.002_bib60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.02.002_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2025.02.002_bib62","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7890","key":"10.1016\/j.semcancer.2025.02.002_bib63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib64","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1038\/s41467-022-33267-z","article-title":"A single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.semcancer.2025.02.002_bib65","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2025.02.002_bib66","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib67","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib68","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-20-3559","article-title":"Multicenter phase I\/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer","volume":"27","author":"Nakajima","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.semcancer.2025.02.002_bib69","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","article-title":"Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Peng","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib70","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-024-00546-y","article-title":"Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma","volume":"13","author":"Luo","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib72","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat. Commun."},{"issue":"28","key":"10.1016\/j.semcancer.2025.02.002_bib73","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cytogfr.2023.08.010","article-title":"Exosome-mediated metabolic reprogramming: implications in esophageal carcinoma progression and tumor microenvironment remodeling","volume":"73","author":"Xi","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.semcancer.2025.02.002_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101149","article-title":"RGS5(+) lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism","volume":"77","author":"Qiu","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.semcancer.2025.02.002_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101126","article-title":"crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib77","article-title":"Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer","volume":"5","author":"Xie","year":"2024","journal-title":"MedComm (2020)"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-022-01307-2","article-title":"Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors","volume":"15","author":"Xu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"Pt 3","key":"10.1016\/j.semcancer.2025.02.002_bib79","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semcancer.2022.03.009","article-title":"Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC","volume":"86","author":"Niu","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib80","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib83","doi-asserted-by":"crossref","first-page":"1338680","DOI":"10.3389\/fimmu.2024.1338680","article-title":"T cell senescence: a new perspective on immunotherapy in lung cancer","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semcancer.2024.08.007","article-title":"cGAS\/STING signalling pathway in senescence and oncogenesis","volume":"106-107","author":"Yu","year":"2024","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib85","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14317","article-title":"Benefit delayed immunosenescence by regulating CD4(+)T cells: a promising therapeutic target for aging-related diseases","author":"Xia","year":"2024","journal-title":"Aging Cell"},{"key":"10.1016\/j.semcancer.2025.02.002_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122631","article-title":"Targeting cellular senescence as a therapeutic vulnerability in gastric cancer","volume":"346","author":"Geng","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.semcancer.2025.02.002_bib87","article-title":"Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids","volume":"598","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.semcancer.2025.02.002_bib88","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib89","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1080\/21655979.2022.2066757","article-title":"An extraction from Trametes robiniophila Murr. (Huaier) inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor","volume":"13","author":"Lv","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.semcancer.2025.02.002_bib90","article-title":"Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharm."},{"issue":"11","key":"10.1016\/j.semcancer.2025.02.002_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002837","article-title":"DPP inhibition alters the CXCR3 axis and enhances NK and CD8+\u2009T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma","volume":"9","author":"Fitzgerald","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.02.002_bib92","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.apsb.2020.02.006","article-title":"Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors","volume":"10","author":"Ma","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-022-01557-1","article-title":"LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer","volume":"21","author":"Shen","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib94","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10637-020-01016-y","article-title":"Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901\/ADR cells","volume":"39","author":"Chu","year":"2021","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib95","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13046-021-01995-7","article-title":"Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-\u0399\u0399","volume":"40","author":"Cai","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"55","key":"10.1016\/j.semcancer.2025.02.002_bib96","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1038\/sj.onc.1204981","article-title":"Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells","volume":"20","author":"Jiang","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2025.02.002_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.918588","article-title":"The antigastric cancer effect of triptolide is associated with H19\/NF-\u03baB\/FLIP Axis","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib98","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1080\/21655979.2021.1945522","article-title":"Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics","volume":"12","author":"Qiu","year":"2021","journal-title":"Bioengineered"},{"issue":"Pt 2","key":"10.1016\/j.semcancer.2025.02.002_bib99","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.semcancer.2022.03.019","article-title":"Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression","volume":"86","author":"Alsayed","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib100","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13046-019-1420-8","article-title":"Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1","volume":"38","author":"D'Alterio","year":"2019","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib102","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","article-title":"Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer","volume":"12","author":"Kumar","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.semcancer.2025.02.002_bib103","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.14336\/AD.2023.0503","article-title":"POSTN Secretion by extracellular matrix cancer-associated fibroblasts (eCAFs) correlates with poor ICB response via macrophage chemotaxis activation of Akt signaling pathway in gastric cancer","volume":"14","author":"You","year":"2023","journal-title":"Aging Dis."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib104","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-021-01127-5","article-title":"Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer","volume":"19","author":"Zheng","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.02.002_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.canlet.2012.01.006","article-title":"Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo","volume":"319","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"15_","key":"10.1016\/j.semcancer.2025.02.002_bib106","article-title":"A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: interim analysis result","volume":"39","author":"Sun","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.02.002_bib107","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00044-022-02890-2","article-title":"Design and synthesis of ludartin derivatives as potential anticancer agents against hepatocellular carcinoma","volume":"31","author":"Sun","year":"2022","journal-title":"Med Chem. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib108","first-page":"69","article-title":"Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma","volume":"9","author":"Lu","year":"2022","journal-title":"Mil. Med Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib109","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/imr.13251","article-title":"Amplifying \"eat me signal\" by immunogenic cell death for potentiating cancer immunotherapy","volume":"321","author":"Xi","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2025.02.002_bib110","first-page":"2756611","article-title":"Definition of a novel cuproptosis-relevant lncRNA signature for uncovering distinct survival, genomic alterations, and treatment implications in lung adenocarcinoma","author":"Wang","year":"2022","journal-title":"J. Immunol. Res 2022"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib112","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1080\/10717544.2022.2079769","article-title":"Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer","volume":"29","author":"Xiao","year":"2022","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.semcancer.2025.02.002_bib113","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1002\/ptr.7158","article-title":"Pleiotropic nature of curcumin in targeting multiple apoptotic-mediated factors and related strategies to treat gastric cancer: a review","volume":"35","author":"Shetty","year":"2021","journal-title":"Phytother. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib114","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5375","article-title":"Curcumin inhibits the cancer\u2011associated fibroblast\u2011derived chemoresistance of gastric cancer through the suppression of the JAK\/STAT3 signaling pathway","volume":"61","author":"Ham","year":"2022","journal-title":"Int J. Oncol."},{"issue":"24","key":"10.1016\/j.semcancer.2025.02.002_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248861","article-title":"Preparation and optimization of O\/W emulsions stabilized by triglycerol monolaurate for curcumin encapsulation","volume":"27","author":"Zhang","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/nano12040696","article-title":"Affibody modified G-quadruplex DNA micelles incorporating polymeric 5-fluorodeoxyuridine for targeted delivery of curcumin to enhance synergetic therapy of HER2 positive gastric cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Nanomater. (Basel)"},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib117","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/s41598-022-05793-9","article-title":"A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment","volume":"12","author":"Yaghoubi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2025.02.002_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112340","article-title":"Improvement of curcumin loading into a nanoporous functionalized poor hydrolytic stable metal-organic framework for high anticancer activity against human gastric cancer AGS cells","volume":"212","author":"Karimi Alavijeh","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib119","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1080\/21655979.2022.2063664","article-title":"Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)\/miR-489-3p\/ eukaryotic translation initiation factor 4A1(EIF4A1) pathway","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/08923973.2021.1936013","article-title":"Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1","volume":"43","author":"Liu","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"48","key":"10.1016\/j.semcancer.2025.02.002_bib121","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.3748\/wjg.v23.i48.8512","article-title":"Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts","volume":"23","author":"Wang","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib122","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-018-0995-9","article-title":"Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2025.02.002_bib123","article-title":"Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer","author":"Wu","year":"2022","journal-title":"Cell Biol. Toxicol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib124","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.molonc.2014.12.009","article-title":"Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition","volume":"9","author":"Liu","year":"2015","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.02.002_bib125","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.7150\/ijbs.65476","article-title":"Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt\/\u03b2-catenin pathway","volume":"18","author":"Dong","year":"2022","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.semcancer.2025.02.002_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106440","article-title":"Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa's cascade underlie its therapeutic effects","volume":"184","author":"Liu","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.semcancer.2025.02.002_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110245","article-title":"Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK\/mTOR\/p70S6K and Akt signaling pathways","volume":"128","author":"Zhang","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib128","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.7150\/thno.53169","article-title":"NEK9, a novel effector of IL-6\/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation","volume":"11","author":"Lu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2025.02.002_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120266","article-title":"Berberine inhibits gastric cancer development and progression by regulating the JAK2\/STAT3 pathway and downregulating IL-6","volume":"290","author":"Xu","year":"2022","journal-title":"Life Sci."},{"issue":"22","key":"10.1016\/j.semcancer.2025.02.002_bib130","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.lfs.2013.09.010","article-title":"Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine","volume":"93","author":"Shi","year":"2013","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.semcancer.2025.02.002_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23354","article-title":"Quercetin handles cellular oxidant\/antioxidant systems and mitigates immunosenescence hallmarks in human PBMCs: an in vitro study","volume":"37","author":"Bouamama","year":"2023","journal-title":"J. Biochem Mol. Toxicol."},{"issue":"19","key":"10.1016\/j.semcancer.2025.02.002_bib132","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.18632\/aging.204275","article-title":"Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle","volume":"14","author":"Liu","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"7861","key":"10.1016\/j.semcancer.2025.02.002_bib133","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-021-03547-7","article-title":"An aged immune system drives senescence and ageing of solid organs","volume":"594","author":"Yousefzadeh","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib134","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/rej.2012.1321","article-title":"Dietary intake of resveratrol enhances the adaptive immunity of aged rats","volume":"15","author":"Yuan","year":"2012","journal-title":"Rejuvenation Res"},{"issue":"3-4","key":"10.1016\/j.semcancer.2025.02.002_bib135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.vetimm.2014.12.004","article-title":"Resveratrol decreases oxidative burst capacity and alters stimulated leukocyte cytokine production in vitro","volume":"163","author":"Woode","year":"2015","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib136","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clinthera.2019.02.001","article-title":"Chronic Low-grade Inflammatory Phenotype (CLIP) and senescent immune dysregulation","volume":"41","author":"Chen","year":"2019","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2025.02.002_bib137","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s00394-018-01890-6","article-title":"Diet supplemented with phytochemical epigallocatechin gallate and probiotic Lactobacillus fermentum confers second generation synbiotic effects by modulating cellular immune responses and antioxidant capacity in aging mice","volume":"58","author":"Sharma","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.semcancer.2025.02.002_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109068","article-title":"Long-term consumption of green tea EGCG enhances murine health span by mitigating multiple aspects of cellular senescence in mitotic and post-mitotic tissues, gut dysbiosis, and immunosenescence","volume":"107","author":"Sharma","year":"2022","journal-title":"J. Nutr. Biochem"},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib139","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s11684-021-0870-5","article-title":"Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients with pneumoconiosis: a pilot double-blind, randomized, and placebo-controlled study","volume":"16","author":"Li","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.semcancer.2025.02.002_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154497","article-title":"Traditional Chinese medicine Pingchan granule for motor symptoms and functions in Parkinson's disease: a multicenter, randomized, double-blind, placebo-controlled study","volume":"108","author":"Gu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.semcancer.2025.02.002_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110440","article-title":"Modified Jian-pi-yang-zheng decoction inhibits gastric cancer progression via the macrophage immune checkpoint PI3K\u03b3","volume":"129","author":"Yuan","year":"2020","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.semcancer.2025.02.002_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154229","article-title":"Effect of modified Jianpi Yangzheng on regulating content of PKM2 in gastric cancer cells-derived exosomes","volume":"103","author":"Wu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.semcancer.2025.02.002_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104623","article-title":"Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1\/PD- L1-dependent T cell immunization","volume":"152","author":"Xu","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.semcancer.2025.02.002_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115085","article-title":"Bioactive components of Banxia Xiexin Decoction for the treatment of gastrointestinal diseases based on flavor-oriented analysis","volume":"291","author":"Wang","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.02.002_bib145","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.4998","article-title":"Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL\u20116\/JAK\/STAT3\u2011mediated PD\u2011L1 activity","volume":"48","author":"Feng","year":"2021","journal-title":"Int J. Mol. Med"},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib146","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib147","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12951-019-0484-0","article-title":"A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients","volume":"17","author":"Hafizi","year":"2019","journal-title":"J. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib148","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2025.02.002_bib149","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2019.12.011","article-title":"Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a prospective self-controlled trial","volume":"49","author":"Kanbayashi","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.semcancer.2025.02.002_bib150","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.2147\/IJN.S253599","article-title":"Mapping intellectual structure and research performance for the nanoparticles in pancreatic cancer field","volume":"15","author":"Zhu","year":"2020","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.semcancer.2025.02.002_bib151","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fonc.2019.00978","article-title":"Development of triptolide self-microemulsifying drug delivery system and its anti-tumor effect on gastric cancer xenografts","volume":"9","author":"Xie","year":"2019","journal-title":"Front Oncol."},{"issue":"15","key":"10.1016\/j.semcancer.2025.02.002_bib152","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"(64)Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2025.02.002_bib153","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.02.002_bib154","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.34019","article-title":"Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): a randomized, open-label, phase 3 trial in Asian patients","volume":"128","author":"Chung","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2025.02.002_bib155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2020.02.002","article-title":"Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric\/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study","volume":"129","author":"Kawazoe","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2025.02.002_bib156","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1535-7163.MCT-21-0273","article-title":"Safety, efficacy, and biomarker results from a phase Ib study of the anti-DKK1 antibody DKN-01 in combination with pembrolizumab in advanced esophagogastric cancers","volume":"20","author":"Klempner","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.semcancer.2025.02.002_bib157","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003518","article-title":"Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study","volume":"10","author":"Yoshikawa","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2025.02.002_bib158","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival","volume":"9","author":"Shah","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2025.02.002_bib159","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.02.002_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J. Immunother. Cancer"}],"updated-by":[{"DOI":"10.1016\/j.semcancer.2025.11.013","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:53:24Z","timestamp":1763751204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":160,"alternative-id":["S1044579X25000124"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.02.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reshaping the immune microenvironment and reversing immunosenescence by natural products: Prospects for immunotherapy in gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}